Maternal and perinatal outcomes of pregnancy associated with COVID-19: Systematic review and meta-analysis

Zekiye Karaçam1, Damla Kızılca-Çakaloğlu1, Gizem Güneş-Öztürk1, Ayden Çoban1

ABSTRACT

INTRODUCTION This study explored maternal and infant outcomes in the periods of pregnancy, birth, and the postpartum, in women with COVID-19.

METHODS After PROSPERO registration (CRD42020191106), scanning for the studies was carried out over the period 5–15 May 2020 in the PubMed, Science Direct, EBSCO and Web of Science databases with the search string: ['COVID-19' AND ('pregnancy' OR 'pregnant' OR 'maternal outcomes' OR 'infant outcomes' OR 'fetal outcomes' OR 'birth')]. Studies reporting maternal and perinatal outcomes of pregnant women with COVID-19 were included. Data were extracted independently by two researchers and combined with meta-analysis and pooled analysis.

RESULTS The 54 studies included in this analysis contained data on 517 pregnant women diagnosed with COVID-19 and 385 infants. Of the pregnant women, 18% had gone into preterm labor and 77% had given birth by caesarean. Of the newborns, 19% had low birth weight, 14% had fetal distress, and 24% were admitted into the neonatal intensive care unit. Nine maternal and eight baby mortalities were reported in the studies.

CONCLUSIONS The study revealed that COVID-19 in pregnant women appeared to be negative maternal and infant outcomes, with mortalities as well.

INTRODUCTION

In February 2020, the World Health Organization (WHO) reported the rapidly spreading global outbreak of a new (novel) coronavirus disease, COVID-19, that had appeared in the last part of 2019 in the city of Wuhan, China. WHO announced that COVID-19 was a pandemic that was an international threat and a global public health emergency1. Over the last two years, this pandemic has caused significant changes in the daily life of people, especially in education and working conditions, in addition to mortality and morbidity rates. During this period, significant progress has been made in the fight against the pandemic with effective health policies, lifestyle changes and widespread vaccination programs. However, especially due to the emergence of new variants, COVID-19 has still not been fully controlled. Efforts to control the pandemic have caused unprecedented economic and social disruption all over the world2,4.

The immune system of the pregnant woman, the changes in her cardiopulmonary, respiratory and physiological systems put her at high risk in terms of becoming infected with respiratory viruses and developing more severe disease. Studies conducted so far have not provided any evidence that pregnant women are any more susceptible to COVID-19 than others4–6. However, the course of disease seems to be worse in pregnant women compared to non-pregnant women of the same age. Although more than 90% of pregnant women with COVID-19 recover without serious morbidity, rapid deterioration of disease may be observed; especially symptomatic pregnant women have a higher risk for severe disease compared to the symptomatic non-pregnant women with COVID-192,7,8.

Current studies to date have shown that pregnant women with COVID-19 are at higher risk for serious illness, need for mechanical ventilation, admission to the intensive care unit, and maternal death. In addition, obstetric complications such as preeclampsia, preterm birth, and premature rupture of membranes, fetal distress, and stillbirth are more common...
in pregnancies complicated by COVID-19\textsuperscript{9,10}. Moreover, some recent publications show that pregnant women infected with new SARS-CoV-2 variants have a worse prognosis\textsuperscript{11,12}. In a study comparing pre-variant and post-variant pregnant groups in Turkey, it was reported that there was a significant increase in the rates of serious and critical cases and in the rates of pregnancy complications, preterm delivery, respiratory support, intensive care unit admission and maternal death, and admission to NICU in the post-variant group\textsuperscript{9}. Although there is evidence of intrauterine transmission of SARS-CoV-2, it is reported to occur rarely\textsuperscript{2}.

Health professionals have an important responsibility in the periods of pregnancy, birth and the postpartum, not only to provide follow-up and care for both mother and child but also to offer preventive, early diagnosis, treatment and individualized care services\textsuperscript{13-15}. Vaccination appears to be one of the most effective means of protection in the COVID-19 pandemic. COVID-19 vaccines approved by the U.S. Food and Drug Administration can be administered to pregnant or lactating women\textsuperscript{2}. In the management process of the COVID-19 pandemic, health professionals need to manage the perinatal period more effectively, using a range of comprehensive knowledge to protect and improve maternal and infant health. They can carry out their follow-up and care services in the perinatal process in accordance with the guidelines published by both national and international sources\textsuperscript{13-15}, thus contributing to the production of more comprehensive scientific knowledge.

During the planning and execution of this study, a look into the literature brings forth systematic reviews, case reports, case series and retrospective cross-sectional international studies conducted with small samples that report perinatal outcomes for pregnant women with COVID-19. However, two systematic review studies have recently been published covering approximately the same time as our study. In these systematic reviews, important information about the effects of COVID-19 infection on mother-infant health has been revealed\textsuperscript{9,10}. On the other hand, there is still an urgent need for high quality evidence-backed scientific studies that will disclose broader sets of data on the subject. It was for this reason that this systematic review and meta-analysis was conducted to examine the maternal and infant health outcomes of pregnant women with COVID-19 during the pregnancy, birth and postpartum periods.

**METHODS**

Protocol and registration

The protocol of this systematic review and meta-analysis was registered on the PROSPERO database (CRD42020191106; registered 11 June 2020). The review and its reporting were followed up on PRISMA (Preferred Reporting items for Systematic Review and Meta-Analysis)\textsuperscript{16}. To keep the risk of bias under control during the study, the scanning, selection of articles, data extraction as well as the quality assessment of the articles included were handled independently by two researchers. Whenever a difference of opinion came up with regard to any aspect of the study, all of the researchers held a discussion session together and arrived at an agreement. At the same time, prior to the start of the study, a pilot study that included all the stages of the research was conducted with the participation of all of the authors, who concurred on a common road map.

Eligibility criteria

The research included those studies published in English between 1 December 2019 and 15 May 2020 and whose full texts could be accessed. The PICOS criteria were considered in the selection of the studies that would be suitable for this systematic review and meta-analysis (Table 1). The exclusion criteria encompassed traditional and

---

**Table 1. PICOS criteria for inclusion of studies and data extraction**

| Parameters (PICOS)       | Inclusion criteria                                                                 | Extraction criteria                                                                 |
|--------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Population               | Pregnant women with COVID-19                                                       | Country, age                                                                        |
| Exposure                 | COVID-19                                                                           | COVID-19 test outcomes                                                              |
| Comparators              | None                                                                               | -                                                                                    |
| Outcomes                 | Data on COVID–19                                                                   | Symptoms of COVID–19, comorbidities, methods of diagnosis and treatment             |
|                          | Presence of data on pregnant women                                                 | Gestation period (weeks), preterm labor, delivery mode, caesarean indications,     |
|                          |                                                                                   | pregnancy-related disorders, admission to the intensive care unit, mechanical       |
|                          |                                                                                   | ventilation, postpartum health status, explanation of the care process, maternal    |
|                          |                                                                                   | death                                                                               |
|                          | Data on baby’s health                                                             | Birth weight, premature, low birth weight, APGAR score 1 and 5 min, fetal distress,|
|                          | Presence of data on newborns                                                       | asphyxia, NICU acceptance, feeding, fetal anomaly, intrauterine and neonatal        |
|                          |                                                                                   | death, IgG, IgM, RT-PCR test and chest radiograph outcomes, follow-up and the       |
|                          |                                                                                   | methods used in its maintenance                                                   |
| Study design             | Case reports, case series, case-control studies, retrospective and prospective      | Design of studies                                                                   |
|                          | observational studies                                                             |                                                                                     |

---

Eur J Midwifery 2022;6(July):42
https://doi.org/10.18332/ejm/149485
systematic reviews and letters to the editor that did not refer to specific cases.

**Searching strategy**
The scanning for this systematic review and meta-analysis was carried out over the period 5–15 May 2020 independently by two of the researchers. Scanning for the international studies was carried out in the PubMed, Ovid, Science Direct, EBSCO and Web of Science, Google Scholar electronic databases with the search string: ['COVID-19' AND ('pregnancy' OR 'pregnant' OR 'maternal outcomes' OR 'infant outcomes' OR 'fetal outcomes' OR 'birth')]. At the same time, additional studies were independently checked by the other two authors against the included articles and the reference lists for the review studies.

**Selection of studies**
Through the processes of scanning, selection according to heading and/or abstract, and the elimination of repetitious articles. The four authors then met together to decide upon the studies that could be taken into the analysis on the basis of full texts. Later, some studies were eliminated from the scope of the analysis during the extraction or analysis processes because they did not contain data appropriate for the analysis. The selection process for the articles can be seen in Figure 1 with a PRISMA flow diagram.

**Data extraction**
The researchers devised a data extraction instrument to be used in obtaining study data (Table 2). This tool made it possible to collect information on the studies included in the systematic review and meta-analysis in terms of author information, the country and year of publication, data collection dates, design, sample size, maternal age and other main findings reported in the studies (Table 1). In four studies of case-control design, only the data pertaining to the cases (pregnant women diagnosed with COVID-19) were extracted.

**Methodological quality evaluation of the studies**
The checklists drawn up by the Joanna Briggs Institute for cross-sectional studies, case studies, case series and case-control studies were used in the quality assessment of the articles. The first and second of these tools comprise eight...
### Table 2. Characteristics and main findings of the studies included in the systematic review and meta-analyses

| Study and Country             | Date of data collection | Study design | Sample size Age (years) | Data on COVID-19 | Data on pregnancy, birth and maternal health | Data on baby’s health | Quality score |
|------------------------------|-------------------------|--------------|-------------------------|-------------------|---------------------------------------------|-----------------------|---------------|
| Alzamora et al.58 Peru        | 29 March 2020           | Case report  | n=1 44                  | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, preterm delivery | Birth weight, 1 and 5 min APGAR score, intubation NICU admission, IgG, IgM and RT-PCR test outcomes, breastfeeding | Yes: 7/8       |
| Breslin et al.29 USA          | 13–27 March 2020        | Retrospective| n=43 Mean: 29.7±6.0     | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, pregnancy-related disorders, mode of delivery, caesarean indications, ICU admission, antepartum and postpartum hospitalization and treatment protocol, explanation of the care process | 1 and 5 minutes APGAR score, NICU admission, prematurity, additional diagnoses, RT-PCR test outcomes, breastfeeding | Yes: 6/8       |
| Browne et al.18 Colombia      | -                       | Case report  | n=1 33                  | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, pregnancy-related disorders, explanation of the care process | -                     | Yes: 7/8       |
| Buonsenso et al.19 Italy      | -                       | Case series  | n=2 38 and 42           | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, explanation of the care process | Birth weight, 1 and 5 min APGAR score, fetal distress, NICU admission, IgG, IgM and RT-PCR test outcomes, breastfeeding | Yes: 9/10      |
| Cao et al.37 China            | 23 January – 23 February 2020 | Retrospective | n=10 (Twins: 1) 29 (n=4), 30 (n=2), 31 (n=2), 35 (n=1) | Symptoms, diagnostic test | Gestational period (weeks), preterm delivery, pregnancy-related disorders, mode of delivery, caesarean indications, explanation of the care process | Birth weight, prematurity, 1 and 5 min APGAR score, fetal distress, neonatal asphyxia, neonatal death; RT-PCR test outcomes | Yes: 6/8       |
| Chen et al.38 China           | 20–31 January 2020      | Retrospective | n=9 26 (n=3), 27, 28, 29, 33, 34, 40 | Symptoms, comorbidities, diagnostic test | Gestational period (weeks), preterm delivery, pregnancy-related disorders, mode of delivery | Birth weight, low birth weight, prematurity, 1 and 5 min APGAR score, fetal distress, neonatal asphyxia, intrauterine and neonatal death, RT-PCR test outcomes | Yes: 6/8       |
| Chen et al.39 China           | 8 December 2019 – 20 March 2020 | Retrospective | n=118 Median 31 (range: 28–34) (Twins: 2) | Symptoms, diagnostic test, treatment protocol | Preterm delivery, maternal death, mode of delivery, caesarean indication, abortion | 1 min APGAR score, neonatal death, neonatal asphyxia; RT-PCR test outcomes | Yes: 6/8       |
| Chen et al.56 China           | 20 January –10 February 2020 | Case series  | n=5 25, 29 (n=2), 30, 31 | Symptoms, diagnostic tests | Gestational period (weeks), pregnancy-related disorders, mode of delivery, postpartum health status | Birth weight, 5 min APGAR score, fetal tachycardia, RT-PCR test outcomes, feeding | Yes: 10/10     |

Continued
### Table 2. Continued

| Study and Country | Date of data collection | Study design | Sample size (Age (years)) | Data on COVID-19 | Data on pregnancy, birth and maternal health | Data on baby's health | Quality score |
|-------------------|-------------------------|--------------|---------------------------|------------------|---------------------------------------------|-----------------------|--------------|
| Chen et al.⁴₀ China | 22–28 February 2020     | Case series  | n=4 (23, 28, 31, 34)     | Symptoms, comorbidities, diagnostic test | Gestational period (weeks), pregnancy-related disorders, mode of delivery, explanation of the care process, postpartum health status | Birth weight, 1 and 5 min APGAR score, fetal distress, NICU admission, RT-PCR test outcomes, feeding | Yes: 9/10    |
| Dong et al.⁵₉ China | 28 January –28 February 2020 | Case report  | n=1 29                   | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, explanation of the care process | Birth weight, 1 and 5 min APGAR score, NICU admission, IgG, IgM and RT-PCR test outcomes | Yes: 7/8    |
| Fan et al.⁵⁷ China | 10 January –27 February 2020 | Case series  | n=2 29, 34               | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, explanation of the care process | Birth weight, 1 and 5 min APGAR score, RT-PCR and Chest CT test outcomes, feeding | Yes: 9/10    |
| Ferrazia et al.⁴¹ Italy | 1–20 March 2020         | Retrospective | n=42 (21–44)             | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), pregnancy-related disorders, ICU admission, mode of delivery, caesarean indications, postpartum health status, explanation of the care process | Birth weight, 5 min APGAR score, NICU admission, RT-PCR test outcomes, feeding | Yes: 6/8     |
| Gidlof et al.⁵₀ Sweden | -                       | Case report   | n=1 (Twins: 1) 34       | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), pregnancy-related disorders, mode of delivery, explanations of the care process | Birth weight, low birth weight, 1 and 5 min APGAR score, NICU admission, RT-PCR test outcomes, feeding | Yes: 7/8     |
| Govind et al.⁴₂ United Kingdom | 7 March – 22 April 2020 | Case series  | n=9 median: 31 (range: 18–39) | Symptoms, diagnostic test, comorbidities | Gestational period (weeks), preterm delivery, pregnancy-related disorders, mode of delivery, caesarean indications, explanations of the care process | Birth weight, low birth weight, 1 and 5 min APGAR score, NICU admission, mechanical ventilation, RT-PCR test outcomes, feeding | Yes: 9/10    |
| Hantoushzadeh et al.⁴₃ Iran | February –March 2020 | Case series  | n=9 25–49               | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), maternal death, mode of delivery | Birth weight, low birth weight, 1 and 5 min APGAR score, NICU admission, RT-PCR test outcomes, neonatal pneumonia, intrauterine and postpartum infant death | Yes: 10/10   |
| Hirshberg et al.¹¹ United States | -                      | Case series  | n=5 27, 29, 33, 35, 39  | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, mode of delivery, Acute Respiratory Distress Syndrome, ICU admission, mechanical ventilation | Birth weight, low birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes | Yes: 9/10    |
| Iqbal et al.²² United States | -                      | Case report   | n=1 34                  | Symptoms, diagnostic test | Gestational period (weeks), mode of delivery, explanations of the care process | 1 and 5 min APGAR score, feeding | Yes: 7/8     |
| Juusela et al.⁴₄ United States | March 2020             | Case series  | n=2 26, 45              | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), pregnancy-related disorders, mode of delivery explanations of the care process, postpartum health status | Fetal tachycardia | Yes: 9/10    |
| Kalafat et al.⁴₀ United States | 19–29 March 2020   | Case report   | n=1 32                  | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, mode of delivery, explanations of the care process, postpartum health status | Birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes | Yes: 7/8     |

Continued
| Study and Country | Date of data collection | Study design | Sample size | Data on COVID-19 | Data on pregnancy, birth and maternal health | Data on baby's health | Quality score |
|-------------------|-------------------------|--------------|-------------|------------------|----------------------------------------------|-----------------------|--------------|
| Karami et al. | - | Case report | n=1 27 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, ICU admission, explanations of the care process, maternal death | 1 and 5 min APGAR score, intrauterine death | Yes: 7/8 |
| Khan et al. | 28 January – 1 March 2020 | Case series | n=3 27, 28, 33 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, mode of delivery, explanations of the care process | Birth weight, 1 and 5 min APGAR score, NICU admission, RT-PCR test outcomes, neonatal death | Yes: 9/10 |
| Khan et al. | 25 January – 15 February 2020 | Case series | n=17 Mean: 29.29 (range: 24–34) | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, mode of delivery | Birth weight, low birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes, neonatal pneumonia, neonatal death | Yes: 10/10 |
| Koumoutsea et al. | - | Case series | n=2 23, 40 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, postpartum bleeding, explanations of the care process | Birth weight, low birth weight, 1 and 5 min APGAR score, fetal bradycardia, feeding | Yes: 9/10 |
| Lee et al. | 14 February 2020 | Case report | n=1 28 | Symptoms, diagnostic test | Gestational period (weeks), preterm delivery, mode of delivery, cephalopelvic disproportion, explanations of the care process | Birth weight, 1 and 5 min APGAR score, NICU admission, RT-PCR test outcomes | Yes: 6/8 |
| Li et al. | 24 January – 29 February 2020 | Case-control | n=16 Mean: 30.9±3.2 | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm delivery, mode of delivery, pregnancy-related disorders, ICU admission, explanations of the care process, postpartum health status | Birth weight, low birth weight, 1 and 5 min APGAR score, fetal distress, RT-PCR test outcomes | Yes: 7/10 |
| Li et al. | 6 February 2020 | Case report | n=1 30 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, explanations of the care process | RT-PCR test outcomes | Yes: 7/8 |
| Li et al. | 28 January 2020 | Case report | n=1 31 | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery | Premature, neonatal death | Yes: 7/8 |
| Liao et al. | 20 January – 2 March 2020 | Case-control | n=10 27, 29 (n=2), 30 (n=2), 33 (n=2), 36 (n=2) | Symptoms, diagnostic test | Gestational period (weeks), preterm delivery, mode of delivery, pregnancy-related disorders, data on birth, explanations of the care process | Birth weight, premature, 1 and 5 min APGAR score, fetal distress, RT-PCR test and chest radiograph outcomes, hyaline membrane disease, neonatal asphyxia | Yes: 7/10 |
| Liu et al. | 20 January – 10 February 2020 | Prospective/cross-sectional | n=15 Mean: 32±5 (range: 23–40) | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, pregnancy-related disorders, explanations of the care process, postpartum health status | 1 and 5 min APGAR score, fetal distress, neonatal asphyxia, neonatal death, stillbirth | Yes: 6/8 |
### Table 2. Continued

| Study and Country | Date of data collection | Study design | Sample size Age (years) | Data on COVID-19 | Data on pregnancy, birth and maternal health | Data on baby’s health | Quality score |
|-------------------|-------------------------|--------------|-------------------------|------------------|---------------------------------------------|-----------------------|--------------|
| Liu et al. 49 China | 31 January – 29 February 2020 | Prospective/cross-sectional | n=19 | n=19 Median: 31 (range: 27–34) | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, pregnancy-related disorders, explanations of the care process | Birth weight, 1 and 5 min APGAR score, fetal distress, NICU admission, RT-PCR test and chest radiograph outcomes, feeding | Yes: 6/8 |
| Liu et al. 50 China | 2–5 February 2020 | Case series | n=3 | 30 (n=2), 34 | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, explanations of the care process | Birth weight, 1 and 5 min APGAR score, fetal distress, meconium aspiration NICU admission, RT-PCR test outcomes, feeding | Yes: 9/10 |
| Liu et al. 51 China | 8 December 2019 – 25 February 2020 | Case series | n=13 | 22, 24, 26, 28, 29, 30 (n=3), 31, 32, 33, 35, 36 | Symptoms, diagnostic test | Gestational period (weeks), preterm labor, mode of delivery, pregnancy-related disorders, ICU admission, mechanical ventilation, postpartum health status, explanations of the care process | 1 and 5 min APGAR score, fetal distress, stillbirth, RT-PCR test outcomes | Yes: 9/10 |
| Lowe and Bopp 55 Australia | - | Case report | n=1 | 31 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, explanations of the care process | 1 and 5 min APGAR score, RT-PCR test outcomes, feeding | Yes: 7/8 |
| Lu et al. 64 China | 11–27 February 2020 | Case report | n=1 | 22 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, postpartum health status, explanations of the care process | Birth weight, 1 and 5 min APGAR score, fetal distress, RT-PCR and Chest CT test outcomes, feeding | Yes: 7/8 |
| Lyra et al. 66 Portugal | - | Case report | n=1 | 35 | Symptoms, diagnostic test | Gestational period (weeks), mode of delivery, pregnancy-related disorders, explanations of the care process | Birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes | Yes: 7/8 |
| Martinelli et al. 28 Italy | 29 March – 14 April 2020 | Case report | n=1 | 17 | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, caesarean indication | Birth weight, low birth weight, NICU admission | Yes: 7/8 |
| Peng et al. 27 China | - | Case report | n=1 | 25 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery | Birth weight, 1 and 5 min APGAR score, fetal distress, NICU admission, RT-PCR test results | Yes: 7/8 |
| Qiancheng et al. 31 China | 15 January – 15 March 2020 | Case-control | n=28 | Median: 30 (range: 26.75–32.00) | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, medical abortion, explanations of the care process | Birth weight, low birth weight, 1 and 5 min APGAR score, neonatal asphyxia, NICU admission, RT-PCR test outcomes, intrauterine death, postpartum infant death | Yes: 7/10 |
| Song et al. 65 China | 6 February 2020 | Case report | n=1 | 30 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery | Birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes, feeding | Yes: 7/8 |
| Study and Country | Date of data collection | Study design | Sample size | Age (years) | Data on COVID-19 | Data on pregnancy, birth and maternal health | Data on baby’s health | Quality score |
|-------------------|-------------------------|--------------|-------------|-------------|------------------|-----------------------------------------------|-----------------------|---------------|
| Wang et al. 66    | 1–18 February 2020      | Case report  | n=1         | 34          | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, pregnancy-related disorders, amniotic fluid with meconium, postpartum health status | Birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes, feeding | Yes: 7/8 |
| Wang et al. 67    | 2–18 February 2020      | Case report  | n=1         | 28          | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery pregnancy-related disorders, ICU admission | Birth weight, 1 and 5 min APGAR score, NICU admission, RT-PCR test outcomes, feeding | Yes: 7/8 |
| Wen et al. 68     | 4–20 February 2020      | Case report  | n=1         | 31          | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), pregnancy continues | | Yes: 7/8 |
| Wu et al. 52      | 23 January – 10 February 2020 | Retrospective | n=8         | 26, 28, 29, 30 (n=3), 31, 35 | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery pregnancy-related disorders, ICU admission caesarean indications, postpartum health status | Fetal distress | Yes: 6/8 |
| Wu et al. 53      | 31 December 2019 – 7 March 2020 | Retrospective | n=23        | Median: 29 (range: 21–37) | Symptoms, comorbidities, diagnostic test | Gestational period (weeks), mode of delivery pregnancy-related disorders, explanations of the care process | Birth weight, 1 and 5 min APGAR score, fetal hypoxia, RT-PCR test outcomes, clinical diagnostic criteria | Yes: 6/8 |
| Xiong et al. 69   | 29 January – 10 March 2020 | Case report  | n=1         | 25          | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery pregnancy-related disorders | Birth weight, 1 and 5 min APGAR score, fetal distress, IgG, IgM and RT-PCR test outcomes | Yes: 7/8 |
| Xu et al. 54      | 21 January – 9 February 2020 | Retrospective | n=5         | 23, 25, 28, 34 (n=2) | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, pregnancy-related disorders, caesarean indications, postpartum health status, explanations of the care process | Birth weight, 1 and 5 min APGAR score, fetal distress, NICU admission, RT-PCR test outcomes, intrauterine death, postpartum infant | Yes: 6/8 |
| Yang et al. 32    | 20 January – 5 March 2020 | Case-control | n=13        | Mean: 30.2±2.3 | Symptoms | Gestational period (weeks), preterm labor, mode of delivery, pregnancy-related disorders, | | Yes: 7/10 |
| Yang et al. 55    | 20–29 January 2020      | Case series  | n=7         |             | Symptoms, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, pregnancy-related disorders, caesarean indications, explanations of the care process | Birth weight, 1and 5 min APGAR score, NICU admission, RT-PCR test outcomes | Yes: 1/10 |
| Yu et al. 55      | 1 January – 8 February 2020 | Case series  | n=7         | 29, 30, 31, 33, 34 (n=3) | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), mode of delivery, ICU admission, explanations of the care process | Birth weight, low birth weight, 1 and 5 min APGAR score, RT-PCR test outcomes | Yes: 10/10 |
| Zarnaniyan et al. 71 | 7–26 March 2020      | Case report  | n=1         | 22          | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, ICU admission, maternal death, explanations of the care process | Birth weight, low birth weight, 1 and 5 min APGAR score, postpartum fever, RT-PCR test outcomes, feeding | Yes: 7/8 |
| Study and Country | Date of data collection | Study design | Sample size Age (years) | Data on COVID-19 | Data on pregnancy, birth and maternal health | Data on baby’s health | Quality score |
|-------------------|-------------------------|--------------|-------------------------|------------------|---------------------------------------------|------------------------|---------------|
| Zambrano et al.71 Honduras | 9 March 2020 | Case report | n=1 41 | Symptoms, comorbidities, diagnostic test | Gestational period (weeks), preterm labor, mode of delivery, explanations of the care process | Birth weight, low birth weight, fetal anomaly, RT-PCR test outcomes | Yes: 7/8 |
| Zeng et al.34 China | 16 February – 6 March 2020 | Retrospective | n=6 | Symptoms, diagnostic test | Gestational period (weeks), mode of delivery, explanations of the care process | 1 and 5 min APGAR score, IgG, IgM and RT-PCR test outcomes | Yes: 6/8 |
| Zeng et al.35 China | January – February 2020 | Retrospective | n=33 | Symptoms, diagnostic test | Gestational period (weeks), preterm labor, mode of delivery, caesarean indications, pregnancy-related disorders, amniotic fluid with meconium, ICU admission, postpartum health status | Birth weight, prematurity, 1 and 5 min APGAR score, fetal distress, fetal asphyxia, NICU admission, intrauterine death, postpartum infant death, RT-PCR test outcomes, treatment protocol, mechanical ventilation | Yes: 6/8 |
| Zhu et al.36 China | 20 January – February 2020 | Retrospective | n=9 (Twins: 1) 25, 29, 30 (n=4), 34, 35 (n=2) | Symptoms, comorbidities, diagnostic test, treatment protocol | Gestational period (weeks), preterm labor, mode of delivery, explanations of the care process | Birth weight, low birth weight, prematurity, 1 and 5 min APGAR score, fetal distress, RT-PCR test and chest radiograph outcomes, diet, postpartum infant death | Yes: 6/8 |

*Two of the women were still pregnant women. **In this section, those who tested and reported their results were taken.
items, while the third and fourth comprise 10 items. Each item is assessed as Yes, No, Uncertain and Inapplicable. The results of the assessment were presented on the basis of the total number of items considered (number of Yes) as a ‘Quality Score’, given in Table 2.

Synthesis of the data
The data in this systematic review and meta-analysis were combined with a meta-analysis and a consolidated percentage calculation. The data obtained from the studies of retrospective and perspective cross-sectional, case series and case-control design were consolidated in the meta-analysis. The data from the case reports were consolidated by pooled analysis. The Comprehensive Meta-Analysis Version 3-Free Trial (https://www.meta-analysis.com/pages/demo.php) was used for the meta-analysis. The extent of heterogeneity in the studies was assessed with the Cochran Q and Higgins I² tests and it was agreed that the I² rate exceeding 50% was an important indication of heterogeneity. Accordingly, when I² was greater than 50%, the Random effect results, and if the value was less, the Fixed Effect results were considered. The study data were composed of categorical variables and combined point estimates were calculated at a confidence interval (CI) of 95% for each result variable. All of the tests were calculated on a two-tailed basis and p<0.05 was accepted as statistically significant.

RESULTS
Searching results
At the beginning, the results of the scan yielded 732 records from the databases and 33 from additional scans, a total of 765 records. With the exclusion of the records that were repeats, the review carried out according to headings and abstracts yielded the full texts of 60 articles. From the review of the full texts, a total of 54 articles reporting the outcomes of pregnant women with COVID-19 and their infants were selected for the analysis (Figure 1).

Study characteristics
All of the studies (n=54) had been published in English. Twenty-two of the studies were case presentations, 13 were case series, 15 were retrospective (13) and perspective (2) cross-sectional studies, and 4 were case-control. It was noted that the study data had been collected over the period 8 December 2019 – 22 April 2020 and all were published in 2020. In 10 of the studies, no indication had been given as to the date of data collection 18–27. The studies were from in 2020. In 10 of the studies, no indication had been given that the I² rate exceeding 50% was an important indication of heterogeneity. Accordingly, when I² was greater than 50%, the Random effect results, and if the value was less, the Fixed Effect results were considered. The study data were composed of categorical variables and combined point estimates were calculated at a confidence interval (CI) of 95% for each result variable. All of the tests were calculated on a two-tailed basis and p<0.05 was accepted as statistically significant.

Quality assessment results of the studies
The quality assessment scores in the case reports were Yes: 7/8 in 21 studies, and Yes: 6/8 in one study. The quality assessment scores in the case series were Yes: 10/10 in three studies and 9/10 in 11 studies. In all of the retrospective (13) and perspective (2) cross-sectional studies, the quality scores were Yes: 6/8, and in all of the case-control studies, the quality assessment scores were Yes: 7/10 (Table 2). A large majority of the studies reviewed met the criteria for quality assessment, representing a low risk of bias.

Results of the meta-analysis
COVID-19 symptoms in pregnant women
The pooled results of the studies reviewed in this systematic review and meta-analysis indicated that the symptoms of the pregnant women were observed to be high fever in 53% in 29 of the studies 19,21,24,29-33,35,36,38-55 (Z=0.503, p=0.615) and cough in 40% in 28 studies 19,21,24,29-33,35,36,38-45,46-56 (Z= -1.824, p=0.068). In fifteen studies, 21% of the pregnant women with COVID-19 had fatigue/tiredness/myalgia 1,2,9,31,37,47,48,51,54,56 (Z= -9.034, p<0.001). Nineteen studies indicated that 21% of the pregnant women with COVID-19 suffered from dyspnea/shortness of breath18,21,24,29-31,38-44,46-48,51-54,56-59 (Z= -4.755, p<0.001) and 16% showed the symptom of sore throat in eight studies 30,36-38,42,47,48,54,56 (Z= -4.613, p<0.001). In four studies, 16% of the pregnant women with COVID-19 had headache21,29,39,40 (Z= -2.954, p=0.003), 15% had chest pain/tightness in seven studies 29,37,38,40,42,47,48,54 (Z= -8.496, p<0.001), and 13% had phlegm in three studies 46,54,56 (Z= -3.028, p=0.002). In twelve studies, 8% of the pregnant women with COVID-19 complained of diarrhea29,33,36-38,41,46-49,55 (Z= -10.701, p<0.001), while 15% suffered from runny/congested nose in six studies 21,42,46,52,56,57 (Z= -4.177, p<0.001). Three studies indicated that 12% of the pregnant women had chills/shivers37,38,57 (Z= -2.366, p=0.018), one study reported that 7 of 9 pregnant women had anosmia22 (Z=1.562, p=0.118), and another reported that 6 of 9 pregnant women complained of lethargy46 (Z=0.980, p=0.327). Furthermore, according to the pooled results of four studies, about 35% of the cases had been observed to be asymptomatic, but it was seen that this result was not statistically significant 19,48,52,53 (Z= -0.568, p=0.570) (Table 3 and Supplementary file Figure 1).

Diagnostic test results for COVID-19 in pregnant women
According to the pooled results of 31 studies, 80% of the pregnant women tested positive on the RT-PCR test 19,21,24,29,30,32-57 (Z=9.424, p<0.001), and 88% had abnormal chest CTs in 21 studies 30,32-40,43,46-50,52-54,56,57 (Z=8.097, p<0.001). In three studies, 37% of the women had abnormal chest X-rays 24,42,44 (Z= -0.813, p=0.416). Moreover, in the pooled results of four studies 19,34,49,52, 38% of the pregnant women had been diagnosed on the
Table 3. Meta-analysis results of maternal health

| Outcome variables               | Number of studies | Cases/total sample size | Point estimate (95% CI) | I² (%) | Z / p       |
|---------------------------------|-------------------|-------------------------|--------------------------|--------|-------------|
| **Symptom**                     |                   |                         |                          |        |             |
| Fever                           | 29                | 252/486                 | 53 (0.42–0.64)           | 72     | 0.503 / 0.615 |
| Cough                           | 28                | 213/474                 | 40 (0.31–0.51)           | 66     | -1.824 / 0.068 |
| Dyspnea/shortness of breath     | 19                | 53/359                  | 21 (0.13–0.31)           | 58     | -4.755 / <0.001 |
| Tiredness/fatigue/myalgia       | 15                | 62/325                  | 21 (0.17–0.26)           | 29     | -9.034 / <0.001 |
| Diarrhea                        | 12                | 21/306                  | 8 (0.05–0.12)            | 0      | -10.701 / <0.001 |
| Sore throat                     | 8                 | 6/61                    | 16 (0.09–0.28)           | 22     | -4.613 / <0.001 |
| Chest tightness/pain            | 7                 | 29/198                  | 15 (0.11–0.21)           | 0      | -8.496 / <0.001 |
| Runny/congestion nose           | 6                 | 6/61                    | 15 (0.03–0.42)           | 27     | -4.177 / <0.001 |
| Headache                        | 4                 | 18/170                  | 16 (0.06–0.37)           | 70     | -2.954 / 0.003 |
| Phlegm                          | 3                 | 3/27                    | 13 (0.04–0.34)           | 0      | -3.028 / 0.002 |
| Chills/shivering                | 3                 | 1/21                    | 12 (0.03–0.42)           | 32     | -2.366 / 0.18 |
| Anosmia                         | 1                 | 7/9                     | 78 (0.42–0.94)           | NA     | 1.562 / 0.118 |
| Lethargy                        | 1                 | 6/9                     | 67 (0.33–0.89)           | NA     | 0.980 / 0.327 |
| Asymptomatic                    | 4                 | 30/164                  | 35 (0.05–0.83)           | 93     | -0.568 / 0.570 |
| **Diagnostic tests**            |                   |                         |                          |        |             |
| PCR (+)                         | 31                | 419/469                 | 80 (0.75–0.84)           | 39     | 9.424 / <0.001 |
| Abnormal chest CT (+)           | 21                | 285/341                 | 80 (0.77–0.94)           | 56     | 8.097 / <0.001 |
| Abnormal chest X-ray (+)        | 3                 | 5/13                    | 37 (0.15–0.67)           | 30     | -0.813 / 0.416 |
| Clinical findings               | 4                 | 33/91                   | 38 (0.19–0.61)           | 69     | -1.029 / 0.303 |
| **Treatments**                  |                   |                         |                          |        |             |
| Antibiotics                     | 15                | 125/171                 | 87 (0.68–0.96)           | 72     | 3.236 / 0.001 |
| Antivirals                      | 14                | 106/150                 | 75 (0.59–0.87)           | 60     | 2.866 / 0.004 |
| Hydroxychloroquine              | 5                 | 16/61                   | 54 (0.12–0.91)           | 81     | 0.141 / 0.888 |
| Corticosteroids                 | 6                 | 12/56                   | 31 (0.11–0.62)           | 58     | -1.227 / 0.220 |
| Chinese medicine (lianhua-qingwen) | 5                 | 40/44                   | 88 (0.74–0.95)           | 0      | 4.085 / <0.001 |
| Intravenous immunoglobulin      | 2                 | 4/37                    | 11 (0.04–0.26)           | 0      | -3.985 / <0.001 |
| Anticoagulant                   | 1                 | 8/9                     | 89 (0.50–0.99)           | NA     | 1.961 / 0.050 |
| Outpatient treatment/monitoring by phone | 2 | 32/53                   | 77 (0.16–0.98)           | 76     | 0.829 / 0.407 |
| Oxygen support                  | 9                 | 38/118                  | 63 (0.27–0.89)           | 78     | 0.682 / 0.495 |
| Intubation/mechanical ventilation | 4           | 7/144                   | 11 (0.01–0.67)           | 81     | -1.450 / 0.147 |
| **Treatments to prevent premature birth** | | | | | |
| Hydration                       | 2                 | 3/45                    | 15 (0.01–0.76)           | 72     | -1.177 / 0.239 |
| Steroid                         | 2                 | 6/7                     | 76 (0.30–0.96)           | 27     | 1.123 / 0.262 |
| MgSO₄                           | 1                 | 2/2                     | 50 (0.06–0.94)           | NA     | 0.000 / 1.000 |
| **Comorbidities**               |                   |                         |                          |        |             |
| Asthma                          | 4                 | 11/59                   | 19 (0.11–0.31)           | 0      | -4.261 / <0.001 |
| Diabetes mellitus               | 3                 | 5/57                    | 9 (0.04–0.21)            | 0      | -4.813 / <0.001 |
| Hypothyroidism                  | 5                 | 6/70                    | 10 (0.05–0.21)           | 0      | -4.962 / <0.001 |
| Chronic hypertension            | 3                 | 8/64                    | 18 (0.04–0.54)           | 74     | -1.765 / 0.078 |
| Obesity                         | 4                 | 6/18                    | 34 (0.16–0.59)           | 0      | -1.280 / 0.201 |
| Heart disease                   | 2                 | 3/17                    | 34 (0.01–0.97)           | 81     | -0.317 / 0.751 |
| Hepatitis B                     | 3                 | 6/67                    | 9 (0.04–0.19)            | 0      | -5.347 / <0.001 |
Table 3. Continued

| Outcome variables                          | Number of studies | Cases/total sample size | Point estimate (95% CI) | I² (%) | Z / p |
|--------------------------------------------|-------------------|-------------------------|-------------------------|--------|-------|
| Polycystic ovary syndrome                  | 3                 | 4/25                    | 17 (0.06–0.38)          | 0      | -2.803 / 0.005 |
| Thalassemia                                | 1                 | 1/15                    | 7 (0.01–0.35)           | NA     | -2.550 / 0.011 |
| Cholecystitis                              | 1                 | 1/4                     | 25 (0.03–0.76)          | NA     | -0.951 / 0.341 |
| Chronic kidney disease                     | 1                 | 1/5                     | 20 (0.03–0.69)          | NA     | -1.240 / 0.215 |
| Familial neutropenia                       | 1                 | 1/2                     | 50 (0.06–0.94)          | NA     | 0.000 / 1.000 |

Diseases related to pregnancy

| Outcome variables                          | Number of studies | Cases/total sample size | Point estimate (95% CI) | I² (%) | Z / p |
|--------------------------------------------|-------------------|-------------------------|-------------------------|--------|-------|
| Gestational diabetes mellitus             | 11                | 21/181                  | 15 (0.10–0.22)          | 16     | -7.792 / <0.001 |
| Hypertension                              | 6                 | 8/114                   | 9 (0.05–0.18)           | 18     | -5.922 / <0.001 |
| Preeclampsia                              | 7                 | 10/57                   | 20 (0.11–0.34)          | 0      | -3.749 / <0.001 |
| Cholestasis                                | 1                 | 1/43                    | 2 (0.00–0.15)           | NA     | -3.694 / <0.001 |
| Anemia                                     | 2                 | 2/14                    | 16 (0.04–0.46)          | 0      | -2.181 / 0.029 |
| Hypothyroidism                            | 1                 | 1/10                    | 10 (0.01–0.47)          | NA     | -2.084 / 0.037 |
| Decrease in fetal movement                | 2                 | 2/47                    | 8 (0.01–0.53)           | 66     | -1.879 / 0.060 |
| Multiple pregnancy                        | 1                 | 2/118                   | 2 (0.00–0.07)           | NA     | -5.693 / <0.001 |
| Early membrane rupture                    | 8                 | 20/132                  | 17 (0.11–0.25)          | 0      | -6.260 / <0.001 |
| Placental abruption                       | 4                 | 4/40                    | 11 (0.04–0.25)          | 0      | -3.980 / <0.001 |
| Placenta previa                           | 4                 | 4/33                    | 14 (0.05–0.31)          | 0      | -3.400 / 0.001 |
| Polyhydramnios/oligohydramnios            | 2                 | 3/14                    | 21 (0.07–0.50)          | 0      | -1.992 / 0.046 |
| Postpartum bleeding                       | 1                 | 1/2                     | 50 (0.06–0.94)          | NA     | 0.000 / 1.000 |
| Admission to ICU                          | 8                 | 14/162                  | 12 (0.04–0.33)          | 65     | -3.039 / 0.002 |
| Maternal death                            | 2                 | 7/127                   | 12 (0.00–0.99)          | 94     | -0.597 / 0.550 |

Duration of pregnancy and mode of delivery

| Outcome variables                          | Number of studies | Cases/total sample size | Point estimate (95% CI) | I² (%) | Z / p |
|--------------------------------------------|-------------------|-------------------------|-------------------------|--------|-------|
| Caesarean delivery                         | 30                | 314/405                 | 73 (0.68–0.78)          | 44     | 7.979 / <0.001 |
| Indication of COVID-19 for caesarean section | 5       | 56/166                  | 29 (0.14–0.51)          | 78     | -1.672 / 0.061 |
| Indication of obstetric for caesarean section | 8       | 63/176                  | 43 (0.28–0.60)          | 66     | -0.837 / 0.403 |
| Preterm labor (<37 weeks)                  | 17                | 60/348                  | 25 (0.17–0.35)          | 55     | -4.304 / <0.001 |

COVID-19 test results in postpartum period

The first 24 hours

| Outcome variables                          | Number of studies | Cases/total sample size | Point estimate (95% CI) | I² (%) | Z / p |
|--------------------------------------------|-------------------|-------------------------|-------------------------|--------|-------|
| Placenta and umbilical cord blood samples (+) | 8               | 1/43                    | 11 (0.04–0.27)          | 0      | -3.916 / <0.001 |
| Breast milk (+)                            | 6                 | 0/35                    | 9 (0.03–0.26)           | 0      | -3.691 / <0.001 |
| Vaginal swab (+)                           | 2                 | 0/5                     | 14 (0.02–0.58)          | 0      | -1.647 / 0.100 |
| Amniotic fluid (+)                         | 7                 | 0/42                    | 9 (0.03–0.22)           | 0      | -4.158 / <0.001 |
| 2nd-14th day                               |                   |                         |                         |        |       |
| Breast milk (+)                            | 3                 | 2/7                     | 33 (0.09–0.70)          | 0      | -0.900 / 0.368 |
| Vaginal swab (+)                           | 1                 | 0/2                     | 17 (0.01–0.81)          | 0      | -1.039 / 0.299 |

basis of clinical findings (Z= -1.029, p=0.303) (Table 3 and Supplementary file Figure 2).

Treatment methods using for COVID-19 in pregnant women

Fifteen studies taken into the meta-analysis showed that 87% of the pregnant women were treated with antibiotics (Z=3.236, p=0.001), and 75% were given antiviral treatment in 14 studies (Z=2.866, p=0.004, I²=60%). In five studies, 54% of the pregnant women were treated with hydroxychloroquine (Z=0.141, p=0.888), while 31% were treated with corticosteroids in six studies (Z= -1.227, p=0.220). In five studies, 88% of the pregnant women were treated with a Chinese medication (lianhua-gingwen) (Z=4.085, p<0.001). In two studies, 11% of the pregnant women were treated with corticosteroids.
women were given intravenous immunoglobulin\(^1,43\) (Z = -3.985, p < 0.001) and 8 of 9 pregnant women were given anticoagulant treatment in one study\(^45\) (Z = 1.961, p = 0.050). Again, 63% of the pregnant women needed oxygen support in 9 studies\(^29,33,38,41,44,45,50,54,55\) (Z = 0.682, p = 0.495), and 11% were intubated/placed on mechanical ventilation in 4 studies\(^21,39,51,52\) (Z = -1.450, p = 0.147). According to the results of two studies, 77% of the pregnant women with COVID-19 had been treated and followed up as outpatients/by telephone\(^29,37\) (Z = 0.829, p = 0.407) (Table 3 and Supplementary file Figure 3).

This meta-analysis showed that it was reported that in order to prevent preterm labor, 15% were treated with hydration\(^29,44\) (Z = -1.177, p = 0.239), and 6 of 7 pregnant women were given steroids in another two studies\(^21,44\) (Z = 1.123, p = 0.262), and 1 of 2 pregnant women were treated with magnesium sulphate (MgSO\(_4\)) in one other study\(^44\) (Table 3 and Supplementary file Figure 4).

**Comorbidities of pregnant women with COVID-19**

The results of the meta-analysis indicated that 19% of the pregnant women in 4 studies had asthma\(^21,24,29,42\) (Z = -4.261, p < 0.001), and it was reported in 3 studies that 18% of the women suffered from chronic hypertension\(^21,29,30\) (Z = -1.765, p = 0.078). It was reported in 5 studies that 10% of the pregnant women had hypothyroidism\(^31,43,50,53,55\) (Z = -4.962, p < 0.001), and 9% of the pregnant women had diabetes mellitus in three studies\(^21,29,42\) (Z = -4.813, p < 0.001). It was found in 4 studies that 34% were obese\(^21,24,43,44\) (Z = -1.280, p = 0.201), 34% had heart disease in two studies\(^4,48\) (Z = -0.517, p = 0.571). It was reported in three studies that 9% of the pregnant women had Hepatitis B\(^31,53\) (Z = -5.347, p < 0.001) and 17% of the women had polycystic ovary syndrome in three studies\(^30,44,55\) (Z = -2.803, p = 0.005). In one study, 7% of the pregnant women were found to have thalassemia\(^48\) (Z = -2.550, p = 0.011), and 1 of 4 of the pregnant women had cholecystitis in another study\(^40\) (Z = -0.951, p = 0.341). It was noted in one study\(^21\) that 1 of 5 pregnant women had chronic kidney disease (Z = -1.240, p = 0.2015), and 1 of 2 pregnant women had familial neuropenia in another study\(^24\) (Table 3 and Supplementary file Figure 5).

**Additional conditions related to pregnancy**

The pooled results of 11 studies in the meta-analysis showed that about 15% of the pregnant women had gestational diabetes mellitus\(^24,29-31,37,41-44,48,54\) (Z = -7.792, p < 0.001), 6 studies indicated that 9% had hypertension\(^29,31,38,42,44,53\) (Z = -5.922, p < 0.001), and 7 studies reported that 20% had preeclampsia\(^30,35,37,58,44,52,56\) (Z = -3.749, p < 0.001). It was reported in one study that 2% of the pregnant women had cholestasis\(^29\) (Z = -3.694, p < 0.001) and 16% of the pregnant women had anemia in another 2 studies\(^37,40\) (Z = -2.181, p = 0.029). Another study revealed that 10% of the pregnant women had hypothyroidism\(^37\) (Z = -2.084, p = 0.037) (Table 3 and Supplementary file Figure 6).

In another 2 studies, 8% of the pregnant women with COVID-19 exhibited reduced fetal movement\(^29,40\) (Z = -1.879, p = 0.060), 2% of the pregnant women were in multiple pregnancy in another study\(^19\) (Z = -5.693, p < 0.001), and 17% had early membrane rupture in 8 studies\(^30,35-38,49,51,53\) (Z = -6.260, p < 0.001). It was reported that 11% of the pregnant women in 4 studies had placental abruption\(^30,36,37,54\) (Z = -3.980, p < 0.001), 14% of the pregnant women in four studies had placenta previa\(^36,40,48,54\) (Z = -3.400, p = 0.01), and 21% of the pregnant women in 2 studies had polyhydramnios/oligohydramnios\(^30,54\) (Z = -1.992, p = 0.046) (Table 3 and Supplementary file Figure 6).

The pooled results in this meta-analysis showed that 8 studies indicated that 12% of the pregnant women diagnosed with COVID-19 were admitted into the intensive care unit\(^21,29,30,35,41,51,52\) (Z = -3.039, p = 0.002), and 12% of the pregnant women in 2 studies were recorded as maternal mortalities\(^39,43\) (Z = -0.597, p = 0.550). In one other study, it was noted that one of the two pregnant women had postpartum hemorrhage\(^24\). While the postpartum hemorrhage and maternal death results pertaining to the pregnant women with COVID-19 were not statistically significant, data related to admittance into the intensive care unit was statistically significant (Table 3 and Supplementary file Figures 7 and 8).

**Results on pregnancy term and mode of delivery in pregnant women**

Thirty studies examined in this systematic review and meta-analysis provided results on the delivery mode of pregnant women with COVID-19\(^19,21,24,29-44,46,48-57\). The pooled results of these studies were statistically significant in that 73% of the pregnant women with COVID-19 had delivered by caesarean section (Z = 7.979, p < 0.001). According to the results of 5 studies, 29% of the women undergoing caesarean section had a COVID-19 indication\(^35,39,41,42,54\) (Z = -1.872, p = 0.061), and 43% of the pregnant women in 8 studies had undergone caesarean section due to obstetric indications\(^29,33,37,39,42,52,54\) (Z = -0.837, p = 0.403). These results, however, were not statistically significant. It was found that 25% of the pregnant women in 17 studies went into preterm labor and this result was statistical significance\(^21,29-33,35-39,41-45,47,51,54\) (Z = -4.304, p < 0.001) (Table 3 and Supplementary file Figure 9).

**Perinatal results of newborns**

In 15 studies examined in this systematic review and meta-analysis, 25% of the newborns of women with COVID-19 were born with low birth weight (Z < 2500 g)\(^19,21,24,30,31,35,38,42,43,46,54,55\) (Z = -4.772, p < 0.001). It was found that about 11% of the newborns in 26 studies had an APGAR score of <7 in the first minute\(^19-21,24,29-31,33-40,42,43,45,46,48,50,51,53-57\) (Z = -8.527, p < 0.001). It was determined that 9% of the newborns had an APGAR score of <7 in the fifth minute in 27 studies\(^19-21,24,29-31,33-38,40-43,45,46,48,50,51,53-57\) (Z = -9.490, p < 0.001). It was revealed that 23% of the newborns suffered fetal distress in 13 studies\(^19,24,30,35,38,44-48,52\) (Z = -4.591, p < 0.001), and 4% of the newborns had fetal asphyxia in 10 studies\(^31,35-39,47,48,53,55\) (Z = -8.078, p < 0.001) (Table 4 and Supplementary file Figure 10).
In 11 of the studies in the meta-analysis, 28% of the newborns had been admitted into the neonatal intensive care unit (NICU) and this result was statistically insignificant\(^{20,29,31,33-35,40-42,45,49,50}\) (\(Z = -4.993, p = 0.066\)). According to the pooled results of 12 of the studies examined, the neonatal death was observed in 6% of newborns and this result was statistical significance\(^{31,35-39,43,45,47,49,51,53,54,56,57}\) (\(Z = -7.411, p<0.001\)). It was found that the intrauterine death rate was 8% in a meta-analysis based on the results of 5 studies\(^{31,35,36,43,54}\) (\(Z = -4.564, p<0.001\)) (Table 4 and Supplementary file Figures 10–12).

Data on neonatal nutrition and care
In 9 studies examined in this meta-analysis, 36% of the newborns were breastfed by their mothers, who wore masks and strictly complied with hand-washing rules\(^{19,20,24,29,41,42,50,56,57}\) (\(Z = -2.911, p = 0.338\)), and all of the eight newborns were fed formula in three studies\(^{19,20,40}\) (\(Z = 2.057, p = 0.040\)). These results were statistically significant. Again, statistical significance was noted in 14 studies regarding the data that 88% of the newborns were isolated from their mothers\(^{19,30,32-34,40,42,44,45,47,49,50,54,57}\) (\(Z = 5.191, p<0.001\)). In 3 studies, 77% of the newborns were isolated together with their mothers, but this finding was not found to be statistically significant\(^{10,29,41}\) (\(Z = 0.779, p = 0.436\)) (Table 4 and Supplementary file Figure 13).

COVID-19 test outcomes of newborns
The consolidated results of 26 studies in this meta-analysis showed that 8% of newborns of women with COVID-19 the newborns tested positive in the RT-PCR test in the first 24 hours after birth\(^{19-21,29,31-39,41-43,45-47,49-51,53,54,56,57}\) (\(Z = -10.581, p<0.001\)), in 2 studies, 2 of 8 newborns tested positive for IgG\(^{34}\) (\(Z = -1.206, p = 0.228\)), and 3 of 8 newborns tested positive for IgM in two studies\(^{34}\) (\(Z = -0.683, p = 0.495\)) (Table 4 and Supplementary file Figure 14).

The consolidated results of eight studies in this meta-analysis revealed that 10% of the newborns tested positive on the RT-PCR test in the 48th hour and on day 14 postpartum\(^{19,20,30,31,33,37,40,47}\) (\(Z = -4.285, p<0.001\)). It was also seen in another 5 studies\(^{36,40,47,49,57}\) that 31% recorded abnormal results on the chest X-ray/CT (\(Z = -1.199, p = 0.231\)) (Table 4 and Supplementary file Figure 15).

COVID-19 test outcomes in placenta, umbilical blood, breast milk, vaginal swab and amniotic fluid samples
In 8 studies examined, one of the placenta and the umbilical blood samples taken from pregnant women with COVID-19 in the first 24 hours postpartum was

### Table 4. Meta-analysis results on newborn health

| Outcome variables                  | Number of studies | Cases/total sample size | Point estimate (95% CI) | \(I^2\) (%) | Z / p   |
|-----------------------------------|-------------------|-------------------------|-------------------------|-------------|---------|
| Perinatal outcomes                |                   |                         |                         |             |         |
| Low birth weight (<2500 g)        | 15                | 31/162                  | 24 (0.140–0.386)        | 51          | -4.772 / 0.001 |
| Apgar Score in the first minute <7 | 26                | 12/317                  | 11 (0.072–0.167)        | 18          | -8.527 / <0.001 |
| Apgar Score in the fifth minute <7| 27                | 12/594                  | 9 (0.061–0.142)         | 0           | -9.490 / <0.001 |
| Fetal distress                    | 13                | 21/136                  | 23 (0.230–0.333)        | 40          | -4.591 / <0.001 |
| Fetal asphyxia                    | 10                | 3/198                   | 4 (0.020–0.086)         | 0           | -8.078 / <0.001 |
| Admission to ICU of newborn       | 11                | 40/168                  | 28 (0.128–0.515)        | 70          | -4.993 / 0.066 |
| Neonatal death                    | 12                | 4/216                   | 6 (0.033–0.122)         | 0           | -7.411 / 0.0001 |
| Intrauterine death                | 5                 | 2/84                    | 8 (0.029–0.198)         | 22          | -4.564 / <0.001 |
| Feeding and care                  |                   |                         |                         |             |         |
| Breastfeeding                     | 9                 | 33/85                   | 36 (0.148–0.646)        | 53          | -2.911 / 0.338 |
| Formula                           | 3                 | 8/8                     | 86 (0.521–0.972)        | 0           | 2.057 / 0.040 |
| Isolated separate from mother     | 14                | 87/90                   | 88 (0.78–0.94)          | 0           | 5.191 / 0.000 |
| Isolated with mother              | 3                 | 32/62                   | 77 (0.14–0.99)          | 83          | 0.779 / 0.436 |
| COVID-19 test outcomes            |                   |                         |                         |             |         |
| The first 24 hours                |                   |                         |                         |             |         |
| RT-PCR (+)                        | 26                | 9/278                   | 8 (0.05–0.12)           | 0           | -10.581 / <0.001 |
| IgG (+)                           | 2                 | 2/8                     | 29 (0.08–0.64)          | 0           | -1.206 / 0.228 |
| IgM (+)                           | 2                 | 3/8                     | 38 (0.12–0.72)          | 0           | -0.683 / 0.495 |
| 2nd–14th day                      |                   |                         |                         |             |         |
| RT-PCR (+)                        | 8                 | 1/61                    | 10 (0.04–0.23)          | 0           | -4.285 / <0.001 |
| Abnormal chest X-ray / CT         | 5                 | 12/39                   | 31 (0.11–0.62)          | 58          | -1.199 / 0.231 |

Eur J Midwifery 2022;6(July):42
https://doi.org/10.18332/ejm/149485

14
statistically significantly positive \( Z = -3.916, \ p < 0.001 \). On the other hand, samples of breast milk in 6 studies \( Z = -3.691, \ p < 0.001 \), of vaginal swab in 2 studies \( Z = -1.647, \ p = 0.100 \), and of amniotic fluid in 7 studies \( Z = -1.900, \ p = 0.368 \), did not test positive. In days 2–14 postpartum, 7 of 8 samples of breast milk were positive in 3 studies \( Z = -0.900, \ p = 0.368 \), and both of the two vaginal swabs were negative in one study \( Z = -1.039, \ p = 0.299 \) (Table 3 and Supplementary file Figures 16 and 17).

**Pooled analysis results from case reports**

According to the pooled results of the 22 case reports, the most common symptoms among pregnant women recorded in case reports were fever (81.8%), cough (54.5%), fatigue/tiredness/myalgia (40.9%) and dyspnea/shortness of breath (40.9%). It was seen that all of these pregnant women tested negative in the RT-PCR test and 72.2% had normal chest-CT scans; the method of treatment was mostly with antibiotics (68.2%) and antiviral drugs (59.1%). Of the pregnant women, 36.4% had underlying conditions and 36.4% had a history of preterm labor; 75% had delivered by caesarean. Eight mothers were admitted into intensive care and two mothers lost their lives. Six out of 20 newborns were admitted into the NICU, and only 2 were being breastfeed while 11 were separated and isolated from their mothers. It was seen that in 1 of the 13 infants tested in the first 24 hours after birth tested positive on the RT-PCR test and 1 of 3 babies tested positive for IgG and IgM. In the later period (48 hours – 14 days), 2 of the 8 infants tested had positive RT-PCR results (Table 5).

### Table 5. Pooled results of cases

| Data on maternal health | Pooled n (%) | Outcome variables | Pooled n (%) |
|-------------------------|-------------|------------------|-------------|
| **Symptoms (n=22)**     |             | **Treatments (n=22)** |
| Fever                   | 18 (81.8)   | Antivirals       | 13 (59.1)   |
| Chills/shivering        | 3 (13.6)    | Antibiotics      | 15 (68.2)   |
| Cough                   | 12 (54.5)   | Hydroxychloroquine | 3 (13.6)   |
| Phlegm                  | 1 (4.5)     | Corticosteroids  | 8 (36.5)    |
| Sore throat             | 2 (9.1)     | Anticoagulant    | 1 (4.5)     |
| Hoarseness              | 1 (4.5)     | Hydration        | 1 (4.5)     |
| Runny/congestion nose   | 3 (13.6)    | Tocolytic therapy| 3 (13.6)    |
| Tiredness/fatigue/myalgia| 9 (40.9)   | Antenatal steroid| 2 (9.1)     |
| Dyspnea/shortness of breath| 9 (40.9) | Oxygen support   | 6 (27.3)    |
| Headache                | 2 (9.1)     | Intubation/mechanical ventilation | 6 (27.3) |
| Diarrhea                | 1 (4.5)     | Blood transfusion/iron supplement | 4 (24.1) |
| Asymptomatic            | 1 (4.5)     | Traditional Chinese medicine, supportive therapy | 1 (4.5) |
| **Diagnostic tests (n=22)** |           | **Diseases related to pregnancy (n=22)** |
| RT-PCR (+)              | 22 (100)    | Gestational diabetes mellitus | 1 (4.5) |
| Abnormal Chest CT (+)   | 16 (72.2)   | Gestational hypertensin | 1 (4.5) |
| Abnormal Chest X-ray (+) | 6 (27.3)   | Hyperemesis gravidarum | 1 (4.5) |
| Abnormal Chest USG      | 1 (4.5)     | Reflux           | 1 (4.5)     |
| Elevated IgG and IgM    | 1 (4.5)     | Preeclampsia     | 1 (4.5)     |
| With comorbidities (n=22) | 8 (36.4) | Preterm labor (<37 weeks) | 8 (36.4) |
| Comorbidities (n=8)     | Multiple pregnancy | 2 (9.1) |
| Diabetes Mellitus       | 1           | Early membrane rupture | 2 (9.1) |
| Asthma                  | 1           | Admission to ICU (n=22) | 8 (36.4) |
| Hypothyroidism          | 3           | Maternal death (n=22) | 2 (9.1) |
| Migraine                | 1           |                  |             |
| Obesity                 | 1           |                  |             |
| Thalassemia             | 1           |                  |             |

Continued
**DISCUSSION**

This systematic review and meta-analysis present the consolidated results of 54 observational studies, case reports and case series studies reporting the maternal and infant health outcomes during the pregnancy, birth and postpartum periods of pregnant women with COVID-19. The results of these studies are significant since they can contribute to improving the processes of treatment, follow-up and care services offered to pregnant women with COVID-19 and their newborns.

**Outcomes of pregnant women with COVID-19**

This systematic review and meta-analysis revealed that pregnant women with COVID-19 most commonly complained of high fever, chills/shivers, fatigue/tiredness/myalgia, cough, dyspnea/shortness of breath, chest pain/tightness, phlegm, runny nose/congestion, diarrhea, headache and sore throat. Similar results have been reported in previous systematic reviews concerning pregnant women. It was found in this meta-analysis that a large percentage of the pregnant women with COVID-19 tested positive on the RT-PCR (80%), revealed an abnormal chest CT (88%) and that some women displayed abnormal chest X-rays (37%). The results of some studies show that a significant percentage of pregnant women with COVID-19 (38%) were diagnosed with clinical findings. Similarly, Smith et al. also report that approximately 90% of the women in their study were administered the RT-PCR test to confirm the diagnosis, that in 79% of the cases, tests were positive and RT-PCR negative in 23%. The authors reported that 99% of the pneumonia cases were diagnosed with CT findings. De Rose et al. state that the respiratory system samples taken from the women tested positive on the RT-PCR test in almost all of the women (99%). Elshafeey et al. report, however, that most of the women (90%) were tested with RT-PCR for a diagnosis and the infection was confirmed with radiological and clinical findings in a smaller percentage of women (10%). Della Gatta et al. report similar results. These data were similar with the diagnostic tests used with non-pregnant individuals, indicating that more information is needed regarding the effects on pregnant women and infant health of diagnostic tests carried out with radiological methods.

It was noted in this systematic review and meta-analysis that pregnant women with COVID-19 were treated with antiviral drugs, antibiotics, intravenous immunoglobulin,
a Chinese drug, hydroxychloroquine, corticosteroids, anticoagulants and oxygen support. Another study similarly indicated that pregnant women with COVID-19 were commonly treated with antibiotics, oxygen, antiviral drugs and corticosteroids\textsuperscript{75}. It was reported in another study that a significant percentage of hospitalized pregnant women (28\%) were put on oxygen support\textsuperscript{74}. These reports show that pregnant women with COVID-19 were treated similarly to non-pregnant individuals\textsuperscript{78}. There is a need for more data on the outcomes of such treatments on pregnancy and the infant.

In 2 studies examined in this systematic review and meta-analysis, a large majority of the pregnant women with COVID-19 were treated as outpatients or followed up by telephone. Again, it was reported in some studies with respect to preterm labor that hydration, steroid and MgSO\textsubscript{4} therapy was applied to some of the pregnant women. These reported results are valuable in that they indicate that pregnant women with COVID-19 can be followed up with routine care similar to what would be implemented under normal circumstances.

This meta-analysis showed that some pregnant women with COVID-19 had underlying conditions such as diabetes mellitus, asthma, chronic hypertension, hypothyroidism, Hepatitis B, obesity, heart disease and polycystic ovary syndrome. On the other hand, Della Gatta et al.\textsuperscript{72} report no pre-existing comorbidities before the pregnancy. It is known that COVID-19 presents a life-threatening risk when there are comorbidities\textsuperscript{79} and that high-risk pregnant women with a history of chronic disease must particularly be carefully protected, making follow-up a matter of vital importance.

The study revealed that some pregnant women had diabetes mellitus, hypertension, preeclampsia and anemia. In a similar study, Della Gatta et al.\textsuperscript{72} reported that one of the 35 pregnant women had gestational hypertension while another suffered from preeclampsia. These conditions can be life-threatening for pregnant women with COVID-19 and necessitate cautious care and follow-up.

Furthermore, the study demonstrated that some pregnant women have additional conditions during their illness such as reduced fetal movement, multiple pregnancy, early membrane rupture, placental abruption, placenta previa and polyhydramnios/oligohydramnios. A previous study\textsuperscript{6} revealed similar results. These conditions may mean added difficulties in treatment, follow-up and care.

Outcomes related to the gestation period in pregnant women with COVID-19 and their mode of delivery

Our study indicates that preterm labor was observed in about 18\% of the pregnant women with COVID-19. While this percentage is lower in the studies of Della Gatta et al.\textsuperscript{72} and Elshafeey et al.\textsuperscript{6} (12\% and 15\%, respectively), De Rose et al.\textsuperscript{5} and Smith et al.\textsuperscript{74} and Yang et al.\textsuperscript{75} report higher rates (54\%, 64\% and 21\%, respectively). These rates are also higher than what is reported for the general population (11\%)\textsuperscript{78,80}. Preterm birth is closely associated with infant fatality and therefore this information must be carefully taken into consideration in the care and follow-up of infants with COVID-19.

This systematic review and meta-analysis reports that most of the pregnant women with COVID-19 (77\%) were delivered by caesarean section. In some of the studies examined, caesarean childbirth was implemented mostly for obstetric indications (43\%) and for some women for COVID-19 indications (29\%). Elshafeey et al.\textsuperscript{6}, De Rose et al.\textsuperscript{5} and Smith et al.\textsuperscript{74} reported similar caesarean rates in their studies (69\%, 77\% and 80\%, respectively). It can be seen in other studies that the caesarean birth rate in women with COVID-19 is much higher\textsuperscript{72,73,75}. Although these outcomes have not been reported as indications, it is apparent that the caesarean birth rate among pregnant women with COVID-19 is markedly high. This outcome should be assessed in terms of maternal and infant health.

Perinatal outcomes of the newborns of pregnant women with COVID-19

It was noted in this systematic review and meta-analysis that 19\% of the newborns of women with COVID-19 was of low birth weight. A previous study revealed a similar percentage\textsuperscript{6}. Contrary to this data, however, Elshafeey et al.\textsuperscript{6} and Yang et al.\textsuperscript{75} report a lower frequency of low birth weight (8\% and 5.3\%, respectively) while Smith et al.\textsuperscript{74} point to a higher rate (43\%). These results can be associated with the incidence of preterm labor among pregnant women with COVID-19.

It was found in this systematic review and meta-analysis that some infants born of pregnant women with COVID-19 had low APGAR scores (<7) in the first (4.3\%) and fifth minute (4.6\%), suffered from fetal asphyxia and fetal distress (14\%). The incidence of fetal distress was reported as lower in studies by Elshafeey et al.\textsuperscript{6} and Yang et al.\textsuperscript{75} (8\% and 11\%, respectively). De Rose et al.\textsuperscript{5} reported this rate to be 22\%. In Smith et al.\textsuperscript{74}, it was reported that all the newborns in their study exhibited normal APGAR scores. Again, in the study by Yang et al.\textsuperscript{75}, a similar outcome was reported with regard to neonatal asphyxia (1.2\%). These results are significant in that they indicate that infants born of women with COVID-19 must be kept under close scrutiny in the perinatal period.

In some studies that were reviewed for this systematic review and meta-analysis, there were data that indicated that some newborns were being breastfed (33\%). Elshafeey et al.\textsuperscript{6} had presented similar results in their systematic review. These data are valuable in terms of the health of breastfed infants and indicate the need for additional research and the adoption of urgent measures to develop methods by which women with COVID-19 can safely provide their infants with the breast milk they require.

It was seen in the meta-analysis that some newborns of women with COVID-19 were administered various tests in the first 24 hours and later after birth. The analysis showed that some infants tested positive in the first 24 hours and some in the period Day 2 – Day 14 on the RT-PCR test. It was also seen that some infants displayed positive IgG and IgM results in the first 24 hours. It was found in the meta-
Outcomes on admittance of pregnant women with COVID-19 and their infants into the intensive care unit and maternal–infant death

It was noted in this systematic review and meta-analysis that a significant portion of the pregnant women were admitted into the intensive care unit and were administered intubation/mechanic ventilation. Elshafeey et al. similarly reported that some women were admitted into intensive care (4.4%) and were administered mechanical ventilation (1.6%). In the study by Smith et al., it was reported that one woman (4.3%) needed mechanical ventilation and was admitted into the intensive care unit. These results indicated that COVID-19 is a serious health issue that threatens maternal/infant health during the period of pregnancy and beyond.

In all of the studies reviewed for this systematic review and meta-analysis, nine mothers were reported to have lost their lives. In their study of 108 pregnant women, Zaigham and Andersson reported no incidents of maternal mortality. Although the percentage was higher than the general maternal mortality rate, it is lower that the mortality rate reported for SARS-CoV-2 (3.8%)18.

It was again seen in this study that a significant portion of the newborns were admitted into the NICU. Similarly, in some other previously published systematic reviews, it was reported that some infants had been admitted to the neonatal intensive care unit due to an additional symptom or for further care and follow-up6,74. These results may be associated with the high level of premature birth and low birth weight rates.

In all of the studies reviewed for this systematic review and meta-analysis, it was reported that 3 out of 385 infants lost their lives in the intrauterine stage and 5 died as neonates. Smith et al. also reported in the data they presented for 37 infants that one baby had died in the intrauterine and one in the neonatal stages. Moreover, Yang et al. and Zaigham and Andersson reported one mortality in the intrauterine and neonatal stages in their studies. In the systematic review of Elshafeey et al., the authors provided findings from 256 newborns, reporting two stillbirths and one neonatal death. Both De Rose et al. and Della Gatta et al. reported one stillbirth in each of their studies. The rates are higher than in general infant rates and are important in that they indicate that COVID-19 is responsible for increasing infant fatalities.

CONCLUSIONS

We tried in this systematic review and meta-analysis to uncover comprehensive data on the status of pregnant women with COVID-19 and their infants, based on the results of 54 studies. The evidence gathered showed that the symptoms, diagnosis, treatment and comorbidity factors associated with COVID-19 were the same in pregnant women as in non-pregnant women. It was, however, noticeable that morbidity, preterm and caesarean birth rates necessitating admission to the intensive care unit as well as maternal and perinatal death rates were higher in pregnant women with COVID-19 and their infants. It was also found that some babies tested positive in the first 24 hours and on Days 2–14 in the RT-PCR, IgG and IgM tests. An important part of these results is also supported by previous systematic review and meta-analysis studies6,10.

Based on existing data, health professionals play a key role in protecting and improving the health of pregnant women during a pandemic. Besides tending to the needs of the other members of the community in this time, these health professionals must take preventive and risk-reducing measures in their care of the high-risk group of pregnant and possibly pregnant women to ensure that no contact is made with the SARS-CoV-2 infection. Moreover, they need to take into consideration the individual characteristics of each pregnant woman in their effort to protect and improve maternal and infant health, basing their actions on the guidelines to care and follow-up set forth by international organizations. It is necessary also in this period to take the measures that will ensure the prevention of neonatal infection and to develop guidelines that will allow infants to benefit from breast milk. Additionally, scientific studies are needed that will explore the long- and short-term effects of the infection and the impact of care and follow-up services specifically adopted for use during the pandemic on maternal and infant morbidity and mortality.

Strengths and limitations

The high score noted in the current quality assessment of the studies examined in this systematic review and meta-analysis and the wide range of additional resources available for scanning constituted the strengths of the study. Also, the large number of pregnant women and infants whose data were reviewed in this systematic review was another strong point that consequently strengthened the conclusions that were drawn. The study was further strengthened by the fact that the results were based on reliable methods of analysis, the subject matter was examined from different aspects, and the results attained were supported by outcomes reported in previous studies. It can be said, however, that the low extent of homogeneity in the studies reviewed may have weakened the power of the evidence. To keep this factor under control, the Random Effect model was preferred in analyses in which the extent of heterogeneity was high. Other limitations were that only studies published in English were taken into the analysis, most of the studies were based on small sample sizes and were derived from Chinese sources, China being the location where COVID-19 had originated, which also meant that studies published in Chinese and other languages could not be included.
REFERENCES

1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. World Health Organization; 2020. March 11, 2020. Accessed April 8, 2022. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

2. Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022;226(2):177-186. doi:10.1016/j.ajog.2021.08.054

3. Sahin D, Tanacan A, Anuk AT, et al. Comparison of clinical features and perinatal outcomes between pre-variant and post-variant periods in pregnant women with SARS-CoV-2: analysis of 1935 cases. Arch Gynecol Obstet. 2022;1-10. doi:10.1007/s00404-022-06493-5

4. Muhidin S, Behboodi Moghadam Z, Vizheh M. Analysis of Maternal Coronavirus Infections and Neonates Born to Mothers with 2019-nCoV; a Systematic Review. Arch Acad Emerg Med. 2020;8(1):e49. doi:10.22037/aaem.v8i1.656

5. De Rose DU, Piersigilli F, Ronchetti MP, et al. Novel Coronavirus disease (COVID-19) in newborns and infants: what we know so far. Ital J Pediatr. 2020;46(1):56. doi:10.1186/s13052-020-0820-x

6. Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID-19 during pregnancy and childbirth. Int J Gynaecol Obstet. 2020;150(1):47-52. doi:10.1002/ijgo.13182

7. DeBolt CA, Bianco A, Limaye MA, et al. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls. Am J Obstet Gynecol. 2021;224(5):S10.e1-S10.e12. doi:10.1016/j.ajog.2020.11.022

8. Şahin D, Tanaçan A, Webster SN, Moraşoğlu Tekin O. Pregnancy and COVID-19: prevention, vaccination, therapy, and beyond. Turk J Med Sci. 2021;51(S1-1):3312-3326. doi:10.3906/sag-2106-134

9. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320

10. Di Toro F, Gjoka M, Di Lorenzo G, et al. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):36-46. doi:10.1016/j.cmi.2020.10.007

11. Kadiwar S, Smith JJ, Ledot S, et al. Were pregnant women more affected by COVID-19 in the second wave of the pandemic? Lancet. 2021;397(10284):1539-1540. doi:10.1016/S0140-6736(21)00716-9

12. Seasey AR, Blanchard CT, Arora N, et al. Maternal and Perinatal Outcomes Associated With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) Variant. Obstet Gynecol. 2021;138(6):842-844. doi:10.1097/AOG.0000000000004607

13. General information regarding pregnant individuals and COVID-19. American College of Obstetricians and Gynecologists; 2020. July 1, 2020. Accessed April 8, 2022. https://paclac.org/wp-content/uploads/2020/07/ACOG_COVID.pdf

14. Coronavirus (COVID-19), pregnancy and women's health. Royal College of Obstetricians and Gynaecologists; 2022. Accessed April 8, 2022. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/COVID-19-pregnancy/

15. Living guidance for clinical management of COVID-19. World Health Organization; 2021. November 23, 2021. Accessed April 8, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535

17. Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromatısı E, Munn Z, eds. JBI Manual for Evidence Synthesis. JBI; 2020. doi:10.46658/JBIMES-20-08

18. Browne PC, Linfoot JB, Perez-Jorge E. Successful Treatment of Preterm Labor in Association with Acute COVID-19 Infection. Am J Perinatol. 2020;37(8):866-868. doi:10.1056/s-0040-1709983

19. Buonsenso D, Costa S, Sanguinetti M, et al. Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2. Am J Perinatol. 2020;37(8):869-872. doi:10.1055/s-0040-1710541

20. Gidlöf S, Savchenko J, Brune T, Josefsson H. COVID-19 in pregnancy with comorbidities: More liberal testing strategy is needed. Acta Obstet Gynecol Scand. 2020;99(7):948-949. doi:10.1111/aogs.13862

21. Hirshberg A, Kern-Goldberger AR, Levine LD, et al. Care of critically ill pregnant patients with coronavirus disease 2019: a case series. Am J Obstet Gynecol. 2020;223(2):286-290. doi:10.1016/j.ajog.2020.04.029

22. Iqbal SN, Overcash R, Mokhtari N, et al. An Uncomplicated Delivery in a Patient with Covid-19 in the United States. N Engl J Med. 2020;382(16):e34. doi:10.22037/amp.2020.08.1652

23. Lyra J, Valente R, Rosário M, Guimarães M. Cesarean Section in a Pregnant Woman with COVID-19: First Case in Portugal. Acta Med Port. 2020;33(6):429-431. doi:10.20344/amp.13883
European Journal of Midwifery

27. Peng Z, Wang J, Mo Y, et al. Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report. J Infect Public Health. 2020;13(5):818-820. doi:10.1016/j.ijiph.2020.04.004

28. Martinelli F, Ferrazzi E, Ciavarella A, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36-37. doi:10.1016/j.thromres.2020.04.022

29. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020;2(2):100118. doi:10.1016/j.ajogmf.2020.100118

30. Li N, Han L, Peng M, et al. Maternal and Neonatal Outcomes of Pregnant Women With Coronavirus Disease 2019 (COVID-19) Pneumonia: A Case-Control Study. Clin Infect Dis. 2020;71(16):2035-2041. doi:10.1093/cid/ciaa352

31. Qiancheng X, Jian S, Lingling P, et al. Coronavirus disease 2019. J Infect. 2020;81(1):e40-e44. doi:10.1016/j.jinf.2020.04.003

32. Yang H, Sun G, Tang F, et al. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019. J Infect. 2020;81(1):e40-e44. doi:10.1016/j.jinf.2020.04.003

34. Zeng H, Xu C, Fan J, et al. Antibodies in pregnant women with SARS-CoV-2 pneumonia: A retrospective analysis. BJOG. 2020;127(9):1116-1121. doi:10.1111/1471-0528.12678

35. Zeng L, Xia S, Yuan W, et al. Neonatal Early-Onset Infection With SARS-CoV-2 in 10 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020;174(7):722-725. doi:10.1001/jamapediatrics.2020.0878

36. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51-60. doi:10.21037/tp.2020.02.06

37. Cao D, Yin H, Chen J, et al. Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A retrospective study. Int J Infect Dis. 2020;95:294-300. doi:10.1016/j.ijid.2020.04.047

38. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-815. doi:10.1016/S0140-6736(20)30360-3

39. Chen L, Li Q, Zheng D, et al. Clinical Characteristics of Pregnant Women with COVID-19 in Wuhan, China. N Engl J Med. 2020;382(25):e100. doi:10.1056/NEJMc2009226

40. Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr. 2020;8:104. doi:10.3389/fped.2020.00104

41. Ferrazzi E, Frigerio L, Savasi V, et al. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis. BJOG. 2020;127(9):1116-1121. doi:10.1111/1471-0528.12678

42. Govind A, Essien S, Karthikeyan A, et al. Re: Novel Coronavirus COVID-19 in late pregnancy: Outcomes of first nine cases in an inner city London hospital. Eur J Obstet Gynecol Reprod Biol. 2020;251:272-274. doi:10.1016/j.ejogrb.2020.05.004

43. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19. Am J Obstet Gynecol. 2020;223(1):109.e1-109.e16. doi:10.1016/j.ajog.2020.04.030

44. Jaussela A, Nazir M, Gomovsk M. Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. Am J Obstet Gynecol MFM. 2020;2(2):100113. doi:10.1016/j.ajogmf.2020.100113

45. Khan S, Jun L, Nawsherwan, et al. Association of COVID-19 with pregnancy outcomes in health-care workers and general women. Clin Microbiol Infect. 2020;26(6):788-790. doi:10.1016/j.cmi.2020.03.034

46. Khan S, Peng L, Siddique R, et al. Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infect Control Hosp Epidemiol. 2020;41(6):748-750. doi:10.1017/ice.2020.84

47. Liao J, He X, Gong Q, Yang L, Zhou C, Li J. Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic. Int J Gynaecol Obstet. 2020;150(1):53-57. doi:10.1002/ijgo.13188

48. Liu D, Li L, Wu X, et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR Am J Roentgenol. 2020;215(1):127-132. doi:10.2214/AJR.20.23072

49. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Front Med. 2020;14(2):193-198. doi:10.1007/s11684-020-0772-y

50. Liu W, Wang Q, Zhang Q, et al. Coronavirus Disease 2019 (COVID-19) During Pregnancy: A Case Series. Preprints. Preprint posted online February 25, 2020. Accessed April 8, 2022. https://www.preprints.org/manuscript/202002.0373/v1

51. Liu Y, Chen H, Tang K, Guo Y. Withdrawn: Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect. 2020;8:104. doi:10.1007/s11684-020-0772-y

52. Wu C, Yang W, Wu X, et al. Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women. Virol Sin. 2020;35(3):305-310. doi:10.1007/s12250-020-00227-0

53. Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia. Int J Gynaecol Obstet. 2020;150(1):58-63. doi:10.1002/ijgo.13165
54. Xu L, Yang Q, Shi H, et al. Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates. Sci Bull (Beijing). 2020;65(18):1537-1542. doi:10.1016/j.scbib.2020.04.040

55. Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis. 2020;20(5):559-564. doi:10.1016/S1473-3099(20)30176-6

56. Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. J Med Virol. 2020;92(9):1556-1561. doi:10.1002/jmv.25789

57. Fan C, Lei D, Fang C, et al. Perinatal Transmission of 2019 Coronavirus Disease-Associated Severe Acute Respiratory Syndrome Coronavirus 2: Should We Worry? Clin Infect Dis. 2021;72(5):862-864. doi:10.1093/cia/ciaa226

58. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. Am J Perinatol. 2020;37(8):861-865. doi:10.1055/s-0040-1710050

59. Dong L, Tian J, He S, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. JAMA. 2020;323(18):1846-1848. doi:10.1001/jama.2020.4621

60. Kalafat E, Yaprak E, Cinar G, et al. Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol. 2020;55(6):835-837. doi:10.1002/uog.22034

61. Lee DH, Lee J, Kim E, Woo K, Park HY, An J. Emergency cesarean section performed in a patient with confirmed severe acute respiratory syndrome Coronavirus-2 -a case report. Korean J Anesthesiol. 2020;73(4):347-351. doi:10.4097/kja.20116

62. Li J, Wang Y, Zeng Y, et al. Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth. Int J Gynaecol Obstet. 2020;150(1):126-128. doi:10.1002/igjo.13189

63. Li Y, Zhao R, Zheng S, et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerg Infect Dis. 2020;26(6):1335-1336. doi:10.3201/eid2606.200287

64. Lu D, Sang L, Du S, Li T, Chang Y, Yang XA. Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission. J Med Virol. 2020;92(9):1660-1664. doi:10.1002/jmv.25927

65. Song L, Xiao W, Ling K, Yao S, Chen X. Anesthetic Management for Emergent Cesarean Delivery in a Parturient with Recent Diagnosis of Coronavirus Disease 2019 (COVID-19): A Case Report. Transl Perioper Pain Med. 2020;7(3):234-237. doi:10.31480/2330-4871/118

66. Wang S, Guo L, Chen L, et al. A Case Report of Neonatal 2019 Coronavirus Disease in China. Clin Infect Dis. 2020;71(15):853-857. doi:10.1093/cid/ciaa225

67. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm Delivery. Clin Infect Dis. 2020;71(15):844-846. doi:10.1093/cid/ciaa200

68. Wen R, Sun Y, Xing QS. A patient with SARS-CoV-2 infection during pregnancy in Qingdao, China. J Microbiol Immunol Infect. 2020;53(3):499-500. doi:10.1016/j.jmii.2020.03.004

69. Xiong X, Wei H, Zhang Z, et al. Vaginal delivery report of a healthy neonate born to a convalescent mother with COVID--19. J Med Virol. 2020;92(9):1657-1659. doi:10.1002/jmv.25857

70. Zamanian M, Ebadi A, Aghajanpour S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection. Prenat Diagn. 2020;40(13):1759-1761. doi:10.1002/pd.5713

71. Zambrano LI, Fuentes-Barahona IC, Bejarano-Torres DA, et al. A pregnant woman with COVID-19 in Central America. Travel Med Infect Dis. 2020;36:101639. doi:10.1016/j.tmaid.2020.101639

72. Della Gatta AN, Rizzo R, Piliu G, Simonazzi G. Coronavirus disease 2019 during pregnancy: a systematic review of reported cases. Am J Obstet Gynecol. 2020;223(1):36-41. doi:10.1016/j.ajog.2020.04.013

73. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. Acta Obstet Gynecol Scand. 2020;99(7):823-829. doi:10.1111/aogs.13867

74. Smith V,seo D, Warty R, et al. Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review. PLoS One. 2020;15(6):e0234187. doi:10.1371/journal.pone.0234187

75. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review. J Matern Fetal Neonatal Med. 2022;35(8):1619-1622. doi:10.1007/s10916-017-0594-1

76. Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol. 2020;55(5):586-592. doi:10.1002/uog.22014

77. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi:10.1016/j.diabres.2020.108142

78. Singhal A. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-286. doi:10.1007/s12098-020-03263-6

79. Tiensuu H, Haapalainen AM, Karjalainen MK, et al. Risk of spontaneous preterm birth and fetal growth associates with fetal SLIT2. PLoS Genet. 2019;15(6):e1008107. doi:10.1371/journal.pgen.1008107

80. Blencowe H, Cousens S, Chou D, et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10(S1):S2. doi:10.1186/1742-4755-10-S1-S2

81. Maternal mortality. World Health Organization; 2019. September 18, 2019. Accessed April 8, 2022. https://www.who.int/news-room/fact-sheets/detail/
maternal-mortality

PROTOCOL REGISTRATION
Prospero: CRD42020191106. Date of registration: 11 June 2020. Title: Maternal and perinatal conditions of pregnancy in COVID-19: systematic review and meta-analysis

CONFLICTS OF INTEREST
The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING
There was no source of funding for this research.

ETHICAL APPROVAL AND INFORMED CONSENT
Ethical approval and informed consent were not required for this study.

DATA AVAILABILITY
Data sharing is not applicable to this article as no new data were created.

AUTHORS’ CONTRIBUTIONS
ZK and AC contributed to study conception, protocol design, quality assessment of the studies, and manuscript drafting. DKC and GGO performed the literature review, data extraction, statistical analysis and manuscript drafting. All authors agreed on the final version of the manuscript and take responsibility for its content.

PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.